Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma 
Welcome,         Profile    Billing    Logout  
 30 Diseases   8 Trials   8 Trials   318 News 


123456»
  • ||||||||||  ronopterin (VAS203) / Vasopharm, dexanabinol (ETS2101) - e / therap, Ceska Lekarnicka, Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Review, Journal:  Neuroprotective and neuroregenerative drugs after severe traumatic brain injury : A (Pubmed Central) -  Dec 10, 2024   
    No abstract available Some pharmacologic attempts that appeared very promising in experimental settings have had disappointing clinical results (progesterone, cyclosporine
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Review, Journal:  The effectiveness of olfactory training for chronic olfactory disorder following COVID-19: a systematic review. (Pubmed Central) -  Nov 26, 2024   
    Integrating olfactory training with adjuvants like CoUltraPEALut, Cerebrolysin, and oral Vitamin A has demonstrated substantial benefits in enhancing post-COVID-19 olfactory function. Strict adherence to the OT protocol and extending the duration of OT to 3 months or more significantly enhance treatment outcomes.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma, Sanbexin (edaravone dexborneol) / Simcere
    Retrospective data, Review, Journal:  Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis. (Pubmed Central) -  Nov 22, 2024   
    Moreover, ginkgolide, EDV, edaravone dexborneol, and GDLM treatment schemes revealed not only a high total treatment effective rate but also a low rate of treatment inefficacy. When considering the combination of the total treatment effective rate with adverse effect, EDV, ginkgolide, and edaravone dexborneol were revealed as the safest and most effective.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Review, Journal:  Evaluating the Effectiveness of Neuroprotective Strategies in Enhancing Post-stroke Recovery: A Systematic Review of Meta-Analyses and Clinical Trials. (Pubmed Central) -  Nov 14, 2024   
    This systematic review evaluates the effectiveness of various neuroprotective strategies in enhancing recovery following acute ischemic stroke, focusing on interventions such as normobaric oxygen (NBO), lithium, selective serotonin reuptake inhibitors (SSRIs), and Cerebrolysin...SSRIs, particularly fluoxetine, showed moderate success in improving motor recovery, as evidenced by the FLAME (Fluoxetine for Motor Recovery after Acute Ischaemic Stroke) trial and meta-analyses...These findings emphasize the mixed efficacy of these neuroprotective interventions and underscore the necessity for personalized treatment protocols and further large-scale, controlled trials to clarify their roles in clinical practice. This review contributes to the ongoing dialogue on optimizing post-stroke recovery and highlights the critical need for evidence-based neuroprotective strategies.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    New trial:  Cerebrolysin in Critically Ill Patients With Delirium (clinicaltrials.gov) -  Nov 6, 2024   
    P=N/A,  N=500, Enrolling by invitation, 
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Clinical, Journal:  Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study (Pubmed Central) -  Oct 22, 2024   
    This review contributes to the ongoing dialogue on optimizing post-stroke recovery and highlights the critical need for evidence-based neuroprotective strategies. The data obtained indicate the presence of a disease-modifying effect in the annual course of Cerebrolysin and the possibility of using this drug in programs of dementia preventive therapy in people with a high risk of cognitive deficits progression and the dementia development in elderly patients with aMCI.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Pharmacological study of kynurenic acid synthesis in Helix pomatia snail in vitro (MCP Hall A) -  Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_12904;    
    We were interested to investigate the effect of anti-dementia drugs, i.e. cerebrolysin and D-cycloserine, on KYNA synthesis in snail liver homogenate in an in vitro study...The significant effect of anti-dementia drugs on KATs activities to reduce KYNA formation in liver homogenate of snail Helix Pomatia is similar to the effect published in other species, i.e. rat and human, at least in an in vitro study. Pharmacological study in an in vivo on the KYNA modulation in the snail Helix Pomatia is of particular importance.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Cerebrolysin ameliorates age-induced dendritic spine degeneration in the hippocampus and prefrontal cortex in mice (MCP Hall A) -  Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_1135;    
    CBL treatment managed to attenuate these age-induced degenerative features mainly in the hippocampus and prefrontal cortex. Furthermore, we observed an improvement in locomotor activity and recognition memory in old mice treated with CBL compared to their control group.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Journal:  Cerebrolysin Concentrate: Therapeutic Potential for Severe Oral Apraxia After Stroke: A Case Report. (Pubmed Central) -  Aug 8, 2024   
    After rehabilitation and administration of cerebrolysin concentrate, there was a marked recovery within a short period of time to the point where oral intake of a regular diet was possible, indicating a significant improvement in oral apraxia. It is a notable example of the potential therapeutic effect of cerebrolysin concentrate for post-stroke oral apraxia.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Journal:  Astrocytes, reactive astrogliosis, and glial scar formation in traumatic brain injury. (Pubmed Central) -  Jul 11, 2024   
    Statins, cannabinoids, progesterone, beta-blockers, and cerebrolysin demonstrate neuroprotective benefits but most of them have not been studied in the context of astrocytes. In this review, we discuss the cell signaling pathways activated in reactive astrocytes following traumatic brain injury and we discuss some of the potential new strategies aimed to modulate astroglial responses in traumatic brain injury, especially using cell-targeted strategies with miRNAs or lncRNA, viral vectors, and repurposed drugs.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Review, Journal:  Current neuroprotective agents in stroke. (Pubmed Central) -  Jul 1, 2024   
    Several agents were described as neuroprotective up to date; however, there is still debate which to use in the neurorehabilitation of stroke patients, in terms of both efficacy and also safety. In this review, we discuss the agents, citicoline, cerebrolysin and MLC901 (NeuroAiD II), the three agents which have started to be used frequently in neurorehabilitation clinics recently in the light of the current literature.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Enrollment closed, HEOR:  C-REGS2: Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness (clinicaltrials.gov) -  Jun 25, 2024   
    P=N/A,  N=1851, Active, not recruiting, 
    In this review, we discuss the agents, citicoline, cerebrolysin and MLC901 (NeuroAiD II), the three agents which have started to be used frequently in neurorehabilitation clinics recently in the light of the current literature. Recruiting --> Active, not recruiting
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Loss of GABAB receptor 1 signaling facilitates activation of disease-associated microglia in the mouse model of Alzheimer's disease (Exhibit (Pennsylvania Convention Center); In-Person) -  Jun 19, 2024 - Abstract #AAIC2024AAIC_2691;    
    Recruiting --> Active, not recruiting Our findings delineate a novel role of loss of the GABA B R1 signaling in AD-associated DAM activation, and elevating GABA B R1 activity within DAM holds promise for enhancing microglial structure and function, ultimately alleviating AD-like pathology and behavioral deficits in the mouse model of Alzheimer
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Review, Journal:  Cognitive impairment in post-traumatic stress disorder (Pubmed Central) -  Jun 17, 2024   
    Possible pathogenetic mechanisms underlying PTSD are the development of neuroinflammation, oxidative stress and decreased production of neurotrophic factors. One of the promising areas of treatment is the use of Cerebrolysin, which has powerful neurotrophic and anti-inflammatory activity.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Trial completion date, Trial primary completion date:  Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants (clinicaltrials.gov) -  Jun 3, 2024   
    P4,  N=150, Completed, 
    Our findings suggest that this combination therapy could be a promising intervention strategy for stroke. Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Jun 2023 --> Apr 2024
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Review, Journal:  Nature's Toolbox for Alzheimer's Disease: A Review on the Potential of Natural Products as Alzheimer's Disease Drugs. (Pubmed Central) -  May 7, 2024   
    Several observations were deduced, which are: i) several compounds showed cognitive improvement, but these improvements may not extend to AD, ii) compounds that are endogenous to the human body showed better outcomes, and iii) Docosahexaenoic acid (DHA) and cerebrolysin had the most potential as AD drugs among the 13 compounds...Given the diverse pathways that these natural products are involved in, they may potentially produce synergistic effects that would be beneficial in treating AD. Additionally, natural products benefit from both physicochemical properties being in more favorable ranges and active transport playing a more significant role than it does for synthetic compounds.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Preclinical, Journal:  Radioprotective effect of Cerebrolysin in the Rat's Brain Tissues. (Pubmed Central) -  Apr 28, 2024   
    Additionally, natural products benefit from both physicochemical properties being in more favorable ranges and active transport playing a more significant role than it does for synthetic compounds. Our finding suggests that CBL has radioprotective effects on the brain by enhancing antioxidant defense mechanisms.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Trial completion date, Trial primary completion date:  Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy (clinicaltrials.gov) -  Apr 4, 2024   
    P1/2,  N=90, Recruiting, 
    Our results demonstrate for the first time a significant clinical effect of Cerebrolysin in improving functional outcomes in patients with ALS and suggest that Cerebrolysin has potential as a novel therapeutic option for ALS. Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Oct 2024
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Preclinical, Journal:  Cerebrolysin potentiates the antidepressant effect of lithium in a rat model of depression. (Pubmed Central) -  Apr 1, 2024   
    Cerebrolysin contributes to improved clinical efficacy and evaluation indexes while demonstrating favorable safety and economic benefits. The augmentation of lithium with cerebrolysin showed a clear beneficial effect in the present model of depression suggesting the use of cerebrolysin as an adjuvant in antidepressant treatment.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Enrollment status, Trial completion date, Trial primary completion date, Surgery:  Cereb-POD: Cerebrolysin in Prevention of Postoperative Delirium in Cardiac Surgery (clinicaltrials.gov) -  Jan 11, 2024   
    P=N/A,  N=100, Enrolling by invitation, 
    The beneficial effects were significant in those whose estimated on-admission HT risk was either moderate or high. Recruiting --> Enrolling by invitation | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Jun 2024
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Trial completion date, Trial primary completion date, HEOR:  C-REGS2: Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness (clinicaltrials.gov) -  Dec 15, 2023   
    P=N/A,  N=2000, Recruiting, 
    Recruiting --> Enrolling by invitation | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Jun 2024 Trial completion date: Apr 2024 --> Sep 2024 | Trial primary completion date: Oct 2023 --> Apr 2024
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Enrollment open:  CERICA: CERebrolysin In CADASIL (clinicaltrials.gov) -  Dec 5, 2023   
    P2,  N=30, Recruiting, 
    In summary, Cerebrolysin fosters Not yet recruiting --> Recruiting
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Journal:  EFFECT OF INVESTIGATIONAL COMBINATIONS OF NEUROPROTECTANTS ON THE LEVEL OF S 100 AND NSE PROTEIN IN THE BLOOD SERUM OF PATIENTS WITH MODERATE AND SEVERE ISCHEMIC STROKE. (Pubmed Central) -  Nov 26, 2023   
    The lowest effectiveness in the correction of neuroglioproliferative processes was recorded when using only conventional therapy (CT), which was determined according to the Order of the Ministry of Health of Ukraine of 03.08.2012 ?602, without the use of neuroprotectors. Whereas, the use of a neuroprotective combination/complex (NPC) (cerebrolysin+citicoline) in the treatment of ischemic strokes in terms of the effectiveness of correction of neuroglioproliferative processes was 1,7-2,7 times (p<0.01) higher than conventional therapy, and 1,2-1,4 times (p<0.05) higher than treatment that included the use of a neuroprotective combination - cerebrolysin+mexidol.